CN105324113B - 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 - Google Patents

共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 Download PDF

Info

Publication number
CN105324113B
CN105324113B CN201480026349.0A CN201480026349A CN105324113B CN 105324113 B CN105324113 B CN 105324113B CN 201480026349 A CN201480026349 A CN 201480026349A CN 105324113 B CN105324113 B CN 105324113B
Authority
CN
China
Prior art keywords
zoledronic acid
purposes
steroids
osteoarthritis
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480026349.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105324113A (zh
Inventor
凯达·德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voltarra Pharmaceuticals Inc
Original Assignee
Voltarra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voltarra Pharmaceuticals Inc filed Critical Voltarra Pharmaceuticals Inc
Publication of CN105324113A publication Critical patent/CN105324113A/zh
Application granted granted Critical
Publication of CN105324113B publication Critical patent/CN105324113B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CN201480026349.0A 2013-03-08 2014-03-07 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎 Expired - Fee Related CN105324113B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US13/791,685 2013-03-08
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
CN105324113A CN105324113A (zh) 2016-02-10
CN105324113B true CN105324113B (zh) 2018-07-03

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026349.0A Expired - Fee Related CN105324113B (zh) 2013-03-08 2014-03-07 共同施用类固醇和唑来膦酸以预防和治疗骨关节炎

Country Status (12)

Country Link
US (1) US9012432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964209B1 (cg-RX-API-DMAC10.html)
JP (2) JP6839491B2 (cg-RX-API-DMAC10.html)
KR (1) KR102253394B1 (cg-RX-API-DMAC10.html)
CN (1) CN105324113B (cg-RX-API-DMAC10.html)
AU (1) AU2014225373B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021503B1 (cg-RX-API-DMAC10.html)
CA (1) CA2941346C (cg-RX-API-DMAC10.html)
EA (1) EA032067B1 (cg-RX-API-DMAC10.html)
ES (1) ES2904365T3 (cg-RX-API-DMAC10.html)
MX (1) MX377447B (cg-RX-API-DMAC10.html)
WO (1) WO2014138712A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3428178A4 (en) 2016-03-09 2019-09-04 Bio Pep Co., Ltd. PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535152A (zh) * 2000-11-29 2004-10-06 ��˹��ŵ�� 二膦酸类化合物在治疗疼痛方面的应用
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
WO2001047559A1 (fr) * 1999-12-27 2001-07-05 Teikoku Seiyaku Co., Ltd Pastilles a usage externe
EP1402066A4 (en) * 2001-06-08 2008-10-22 Ortho Mcneil Pharm Inc PAIN TREATMENT WITH HYPERPOLARIZATION ACTIVATED CHANNELS CONTROLLED BY CYCLIC NUCLEOTIDE AS ATTACK POINT
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US20100158905A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
EP2427160A4 (en) * 2009-05-04 2012-12-19 Zars Pharma Inc METHOD FOR TREATING PAIN RELATED TO NEUROMAS, NERVE CLAIMS AND OTHER SUFFERING PAINS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535152A (zh) * 2000-11-29 2004-10-06 ��˹��ŵ�� 二膦酸类化合物在治疗疼痛方面的应用
US20110263537A1 (en) * 2010-04-26 2011-10-27 Ketan Desai Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response;Jones A.等;《Ann Rheum Dis》;19961231;第55卷(第11期);第829-832页 *
Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial;Laslett L.L.等;《Ann Rheum Dis》;20121231;第71卷(第8期);第1322-1328页 *

Also Published As

Publication number Publication date
JP6839491B2 (ja) 2021-03-17
MX377447B (es) 2025-03-10
EP2964209A1 (en) 2016-01-13
EA032067B1 (ru) 2019-04-30
CA2941346A1 (en) 2014-09-12
BR112015021503B1 (pt) 2022-09-06
EA201591638A1 (ru) 2016-02-29
ES2904365T3 (es) 2022-04-04
EP2964209B1 (en) 2021-10-27
US9012432B2 (en) 2015-04-21
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
EP2964209A4 (en) 2016-08-03
AU2014225373A1 (en) 2015-10-22
AU2014225373B2 (en) 2018-07-05
CA2941346C (en) 2020-03-10
CN105324113A (zh) 2016-02-10
JP2019104762A (ja) 2019-06-27
BR112015021503A2 (en) 2018-05-15
KR102253394B1 (ko) 2021-05-20
JP2016510765A (ja) 2016-04-11
US20140256681A1 (en) 2014-09-11
WO2014138712A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US9737553B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
CA2941346C (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
JP2021183650A (ja) 治療用組成物、組合せ物および使用の方法
Montgomery et al. Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer
SK13512003A3 (sk) Použitie N-bisfosfonátu na prípravu liečiva na liečenie kostných metastáz spojených s karcinómom prostaty
TW202114677A (zh) 治療組成物、組合及使用方法
Scott et al. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma
JP2015514756A (ja) がんのためのグルフォスファミド組み合わせ療法
JP7574184B2 (ja) 悪性腫瘍の治療方法
Liang et al. Research status on immunotherapy trials of gastric cancer
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
US20060217425A1 (en) Methods of treating cancer using PPAR-gamma antagonists
Hering et al. Clodronate for treatment of bone metastases in hormone refractory prostate cancer
CN105283185A (zh) 用于治疗何杰金氏淋巴瘤的4-氰基-n-(2-(4，4-二甲基环己-1-烯-1-基)-6-(2，2，6，6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-酰胺
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
US20250177352A1 (en) Combination treatment for cancer
RU2816126C2 (ru) Способ лечения злокачественной опухоли
US20240058349A1 (en) Pi3k inhibitors for protection against glucocorticoid-induced atrophy
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
Berdelou et al. Radioiodine Refractory Thyroid Cancer
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180703

CF01 Termination of patent right due to non-payment of annual fee